1st International Course on
Integrated Biomarkers

Biochemical and Bioimaging Endpoints in Cardiocerebrovascular Diagnosis,
Prevention, Therapy and Drug Development


Biomarkers 2005

To facilitate the dialogue among the multidisciplinary scientists, definition of the acronyms and of more specialized terms have been reported. Every amendment is welcome.

Andrea P. Peracino
Stefano Bellosta
Nicola Ferri
Riccardo Roggeri

FDAs primary consideration in determining when a new IVD requires a PMA is the level of risk to patient health that information obtained from use of the IVD may have in the event of an erroneous test result. In this context, FDA seeks to understand whether the proposed new IVD will be used in a manner that will uniquely and substantively affect diagnostic or therapeutic interventions for a particular disease or condition
http://www.fda.gov/cder/drugsatfda/glossary.htm '">


Go back